Solve Therapeutics
Based in California, it employs some twenty researchers and recently acquired Cereius, a pioneer in antibody-based treatments.
Its multi-disciplinary approach has enabled it to advance medicine by creating effective treatments for major psychiatric pathologies (Alzheimer's disease, autism spectrum disorders, etc.) that were previously difficult to treat with drugs.
Led by a team of former researchers from major pharmaceutical companies who bring their solid experience to the company, Solve Therapeutics invests heavily in research and establishes strategic partnerships with renowned academic institutions.
Having raised $126 million, the company has established itself as a major player in psychiatric research in North America just two years after its creation, and aims to consolidate its position through further acquisitions.
